Approach to treatment of metastatic hormone-sensitive prostate (mHSPC) cancer among cooperative oncology groups (CCTG, SWOG, and Alliance) in North America.
Chalker C, Ong M, McKay R, Tangen C, Gulati S, Keim M, Lerner S, Dorff T, Sokolova A. Approach to treatment of metastatic hormone-sensitive prostate (mHSPC) cancer among cooperative oncology groups (CCTG, SWOG, and Alliance) in North America. Journal Of Clinical Oncology 2025, 43: 263-263. DOI: 10.1200/jco.2025.43.5_suppl.263.Peer-Reviewed Original ResearchProstate specific antigenTriplet therapyDoublet therapyGenitourinary oncologistsPatient comorbiditiesClinical trialsVolume of diseaseClinical Trials GroupOptimal clinical settingClinical trial enrollmentRandomized clinical trialsDe novoMHSPC patientsApproach to treatmentDisease volumeSystemic therapyTriple therapyYears of clinical experienceMHSPCSpecific antigenClinician specialtyPatient factorsTrial enrollmentTherapyPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply